Evidence map›Paper›PMID 36900396›Full record

ArticleCancers2023

Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil.

Anna Beatriz Dos Santos Salgado, Roberto Jose Pessoa Magalhães, Robéria M Pontes, Eduarda da Silva Barbosa, Juan Flores-Montero, Luzalba Sanoja-Flores, Marcelo Gerardin Poirot Land, Glicinia Pimenta, Hélio Dos Santos Dutra, Elaine S Costa and 2 more

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anna Beatriz Dos Santos SalgadoInternal Medicine Postgraduate Program, Faculty of Medicine, Department of Internal Medicine, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21044-020, Brazil.
Roberto Jose Pessoa MagalhãesUniversity Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.
Robéria M PontesTranslational Research Laboratory, Children's Hospital of Brasilia Jose Alencar, Brasilia 70684-831, Brazil.
Eduarda da Silva BarbosaInternal Medicine Postgraduate Program, Faculty of Medicine, Department of Internal Medicine, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21044-020, Brazil.
Juan Flores-MonteroTranslational and Clinical Cancer Research Program, Centro de Investigación del Cáncer (CIC-IBMCC-CSIC/USAL), Department of Medicine, Universidad de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0002-1119-4387
Luzalba Sanoja-FloresInstitute of Biomedicine of Seville, Department of Hematology of the University Hospital Virgen del Rocío, University of Seville, 41013 Seville, Spain.ORCID 0000-0002-9275-7793
Marcelo Gerardin Poirot LandInternal Medicine Postgraduate Program, Faculty of Medicine, Department of Internal Medicine, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21044-020, Brazil.ORCID 0000-0001-9792-3167
Glicinia PimentaUniversity Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21941-617, Brazil.
Hélio Dos Santos DutraInstitute of Biomedical Science, Federal University of Rio de Janeiro (ICB/CCS/UFRJ), Rio de Janeiro 21941-590, Brazil.
Elaine S CostaInternal Medicine Postgraduate Program, Faculty of Medicine, Department of Internal Medicine, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21044-020, Brazil.
Alberto OrfaoTranslational and Clinical Cancer Research Program, Centro de Investigación del Cáncer (CIC-IBMCC-CSIC/USAL), Department of Medicine, Universidad de Salamanca, 37007 Salamanca, Spain.ORCID 0000-0002-0007-7230
Angelo MaiolinoInternal Medicine Postgraduate Program, Faculty of Medicine, Department of Internal Medicine, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 21044-020, Brazil.

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior CAPES/PROEX 88887.335769/2019-00Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E01/200/537/2018
6 · The paper itself

Abstract

Despite recent advances in multiple myeloma (MM), the incorporation of novel agents and measurable residual disease (MRD) monitoring in low-income countries remains a challenge. Although lenalidomide maintenance (M-Len) after autologous stem cell transplantation (ASCT) has been associated with improved outcomes and MRD has refined the prognosis of complete response (CR) cases, until now, there have been no data on the benefits of these approaches in Latin America. Here, we evaluate the benefits of M-Len and MRD using next-generation flow cytometry (NGF-MRD) at Day + 100 post-ASCT (

Indexed as

autologous transplantdrug accesslenalidomidemaintenancemeasurable residual diseasemultiple myelomareal-world study

Identifiers

PMID36900396
PMCPMC10000507

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read78
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.